🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsOther Peptides & Research CompoundsLL-37 antimicrobial peptide — immune function research

LL-37 antimicrobial peptide — immune function research

PeptideChemSF Sun, May 17, 2026 at 12:31 PM 20 replies 496 viewsPage 1 of 4
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
May 17, 2026 at 12:31 PM#1

Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.

The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

Where I think it is weakest: the completion rate deserves as much attention as the headline, because a large effect among those who finished is a different claim from a large effect among those enrolled.

The narrow version of the question is which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working. Not looking for reassurance. Looking for the part I have got wrong.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
36 6steve_okc, dave_SLC, FDA_TrackerJim and 33 others
Reply Quote Save Share Report
Dr.RenalNash
VIP Member
1,234
7,890
Mar 2024
Nashville, TN
May 17, 2026 at 1:00 PM#2
PeptideChemSF said:
The mechanism is more central than most summaries suggest.

PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing. Semaglutide:

  • Tmax: 24-72 hours post-injection
  • T½: ~168 hours (7 days) — enables weekly dosing
  • Steady state: reached at 4-5 weeks
  • Bioavailability (SubQ): ~89%
  • Volume of distribution: ~12.5L (primarily plasma)

The albumin binding (>99%) is the key pharmacological innovation — creating a sustained-release effect from a single injection. Previous GLP-1 agonists (exenatide) required BID dosing due to rapid clearance.

35 5pam_stl, wei_SG, cory_ATX and 32 others
Reply Quote Save Share Report
TrialNerd_Beth
Senior Member
2,345
11,234
Jan 2024
Bethesda, MD
May 17, 2026 at 1:29 PM#3
PeptideChemSF said:
The mechanism is more central than most summaries suggest.

I read this differently from PeptideChemSF, on substance rather than tone. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

34 4TomTeleRx, DoseLogDan, SleepFixSam and 31 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
May 17, 2026 at 1:58 PM#4
TrialNerd_Beth said:
The pharmacokinetics explain nearly every practical question asked here.

Pharmacist here. I want to add the drug interaction perspective on the pharmacology.

Key points from a pharmacokinetic standpoint:

  • GLP-1 agonists delay gastric emptying, which can affect Tmax of co-administered oral medications
  • Monitor patients on warfarin (INR), levothyroxine (TSH), and oral contraceptives during dose titration
  • The albumin-binding mechanism of semaglutide (C-18 fatty acid linker) gives it the ~168-hour half-life that enables weekly dosing
  • Steady state is reached at approximately 4-5 weeks after dose initiation or adjustment

Re: the pharmacology specifically — the pharmacology here is well-characterized and the clinical implications are straightforward.

Last edited: May 17, 2026 at 5:58 PM
33 3BethLabQueen, ChrisMacros, KetoKyle and 30 others
Reply Quote Save Share Report
ricardo_MIA
Member
378
1,678
Sep 2024
Miami, FL
May 17, 2026 at 4:36 PM#5
Dr.RenalNash said:
PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing.

Mine went the same way, slower. The detail I would add is minor and it is already implied above.

Last edited: May 17, 2026 at 9:36 PM
32 2ChrisMacros, KetoKyle, CanadaChris and 29 others
Reply Quote Save Share Report

Similar Threads

BPC-157 oral vs injectable — bioavailability review and evidence15 replies
TB-500 for tissue repair — mechanism and clinical evidence4 replies
Selank and Semax — anxiolytic peptides overview2 replies
CJC-1295/Ipamorelin combination — GH secretagogue discussion23 replies
BPC-157 + GLP-1 stacking for gut healing — N=1 experience17 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register